← Back to screener

Silence Therapeutics plc SLN

Rank #2496 · Nasdaq · $2.8B market cap
⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
13.0
P/E
-61.8
P/B
127.25
ROE
-206.0%
Op. Margin
-200.1%
Debt Ratio
312%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -61.8x, P/B 127.25x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -206.0%. Ranks in the top 94% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 312%. Ranks in the top 72% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 46.1% year over year. Ranks in the top 8% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024$0.0B$-0.1B$-0.1B$0.0B-281.9788
2025$0.0B$-0.1B$-0.0B$0.0B-200.1312

← See the full screener